Penthalaris, a novel recombinant five-Kunitz tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick vector of Lyme disease, Ixodes scapularis

Thrombosis and Haemostasis

Volumn 91, Issue 5, 2004, Pages 886-898

  Francischetti, Ivo M B ^a   Mather, Thomas N ^b   Ribeiro, José M C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

Anticoagulant; Inhibitor; Ixodes scapularis; Kunitz; Tick saliva; Tissue factor pathway

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; CHROMOGENIC SUBSTRATE; COMPLEMENTARY DNA; CYSTEINE; DIMER; ENZYME PRECURSOR; MONOMER; PENTHALARIS; PLACENTA PROTEIN 5; RECOMBINANT PROTEIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATTENUATION; BLOOD CLOT LYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; GEL FILTRATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; IMMUNE DEFICIENCY; IXODES SCAPULARIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SALIVARY GLAND; SEQUENCE HOMOLOGY; STOICHIOMETRY;

EID: 2442483514     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-11-0715     Document Type: Article

References (79)

1. Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12.
2. Jenny NS, Mann KG. Coagulation cascade: an overview, in Loscalzo J, Schafer AI (eds.): Thrombosis and Hemorrhage, 2d ed. Baltimore, MD: Williams and Wilkins, 1998, 3-27.
3. Riewald M, Ruf W. Orchestration of coagulation protease signaling by tissue factor. Trends Cardiovasc Med 2002; 12: 149-54.
4. Broze GJ Jr. Tissue factor pathway inhibitor, in Loscalzo J, Schafer AI (eds.): Thrombosis and Hemorrhage, 2d ed. Baltimore, MD: Williams and Wilkins, 1998, 77-104.
5. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165-74.
6. Esmon CT. Regulation of Blood coagulation. Biochim Biophys Acta 2000; 1477: 349-60.
7. Olson ST, Bjork I, Bock SC. Identification of critical molecular interactions mediating heparin activation of antithrombin: implications for the design of improved heparin anticoagulants. Trends Cardiovasc Med 2002; 12: 198-205.
8. Tollefsen DM. Insight into the mechanism of action of heparin cofactor II. Thromb Haemost 1995; 74: 1209-14.
9. Griffin JH. Control of coagulation reactions. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U (eds): Williams Hematology, 6th ed. New York, NY. McGraw-Hill Companies, Inc., 2001, 1435-49.
10. Broze GJ Jr, Warren LA, Novotny WF, et al. The lipoprotein-associated coagulation inhibitor that inhibits the FVII-tissue factor complex also inhibits FXa: insight into its possible mechanism of action. Blood 1988; 71: 335-43.
11. Wun T-C, Kretzmer KK, Girard TJ, et al. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-4.
12. Pedersen AH, Nordfang O, Norris F, et al. Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem 1990; 254: 16786-93.
13. Hamamoto T, Yamamoto M, Nordfang O, et al. Inhibitory properties of full-length and truncated recombinant tisuue factor pathway inhibitor (TFPI). J Biol Chem 1993; 268: 8704-10.
14. Rapaport SI. Inhibition of FVIIa/tissue factor-induced blood coagulation: with particular emphasis upon a FXa-dependent inhibitory mechanism. Blood 1989; 73: 359-65.
15. Huang Z-F, Wun T-C, Broze GJ Jr. Kinetics of FXa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268: 26950-5.
16. Rao LVM, Ruf W. Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor-VIIa with Xa-tissue factor pathway inhibitor. Biochemistry 1995; 34: 10867-71.
17. Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
18. Broze GJ Jr, Girard, TH, Novotony, WF. Regulation of coagulation by multivalent Kunitz-type inhibitor. Biochemistry 1995; 29: 7539-46.
19. Ruf W, Dickinson CD. Allosteric regulation of the cofactor dependent serine protease coagulation factor VIIa. Trends Cardiovasc Med 1988; 8: 350-6.
20. Bogdanov VY, Balasubramanian V, Hathcock J, et al. Alternatively spliced human tissue factor: a circulating soluble, thrombogenic protein. Nat Med 2003; 9: 458-62.
21. Drake TA, Morrisey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am J Pathol 1989; 134: 1087-97.
22. Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci USA 1990; 87: 6995-9.
23. Bach RR, Moldow CF. Mechanism of tissue factor activation on HL-60 cells. Blood 1997; 89: 3270-6.
24. Ruf W, Edgington TS. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J 1994; 8: 385-90.
25. Camera M, Giesen PL, Fallon J. Cooperation between VEGF and TNF-α is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 531-7.
26. Giesen PLA, Nemerson Y. Tissue factor on the loose. Semin Thromb Hemost 2000; 26: 379-84.
27. Ribeiro JM, Francischetti IM. Role of arthropod saliva in blood feeding: sialome and post-sialome perspectives. Ann Rev Entomol 2003; 48: 73-88.
28. Sonenshine DE. Pheromones and other semiochemicals of the acari. Annu Rev Entomol 1985; 30: 1-28.
29. Francischetti IMB, Valenzuela JG, Andersen JF, et al. Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. Blood 2002; 99: 3602-12.
30. Narasimhan S, Koski RA, Beaulieu B, et al. A novel family of anticoagulants from the saliva of Ixodes scapularis. Insect Mol Biol 2002; 11: 641-50.
31. Valenzuela JG, Charlab R, Mather TN, et al. Purification, cloning, and expression of a novel salivary anticomplement protein from the tick, Ixodes scapularis. J Biol Chem 2000; 275: 8717-23.
32. Ribeiro JMC, Makoul GT, Robinson DR. Ixodes dammini: evidence for salivary prostacyclin secretion. J Parasitol 1988; 74: 1068-9.
33. Mans BJ, Louw AI, Neitz AW. Savignygrin, a platelet aggregation inhibitor from the soft tick Ornithodoros savignyi, presents the RGD integrin recognition motif on the Kunitz-BPTI fold. J Biol Chem 2002; 277: 21371-8.
34. Ribeiro JMC, Weis JJ, Telford SR III. Saliva of the tick Ixodes dammini inhibits neutrophil function. Exp Parasitol 1990; 70: 382-8.
35. Francischetti IMB, Mather TN, Ribeiro JMC. Cloning of a salivary gland metalloprotease and characterization of gelatinase and fibrin-(ogen)lytic activities in the saliva of the Lyme disease tick vector Ixodes scapularis. Biochem Biophys Res Commun 2003; 305: 869-75.
36. Tatchell RJ. A modified method for obtaining tick oral secretion. J Parasitol 1967; 53: 1106-7.
37. Francischetti IMB, Valenzuela JG, Pham VM, et al. Toward a catalog for the transcripts and proteins (sialome) from the salivary gland of the malaria vector Anopheles gambiae. J Exp Biol 2002; 205: 2429-51.
38. Valenzuela JG, Francischetti IMB, Pham VM, et al. Exploring the sialome of the tick Ixodes scapularis. J Exp Biol 2002; 205: 2843-64.
39. Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucl Acids Res 1997; 25: 3389-402.
40. Nielsen H, Engelbrecht J, Brunak S, et al. A neural network method for identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng 1997; 10: 1-6.
41. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res 1994; 22: 4673-80.
42. Page RDM. TREEVIEW: An application to display phylogenetic trees on personal computers. Computer Appl Biosci 1996; 12: 357-8.
43. Han X, Girard TJ, Baum P, et al. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat. Arterioscler Thromb Vasc Biol 1999; 19: 2563-7.
44. Francischetti IMB, Andersen JF, Ribeiro JMC. Anophelin: kinetics and mechanism of thrombin inhibition. Biochemistry 1999; 38: 16678-85.
45. Williams JW, Morrison JF. The kinetics of reversible tight-binding inhibition. Methods Enzymol 1979; 63: 437-67.
46. Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human FVIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 1991; 29: 9418-25.
47. Bergun PW, Cruikshank A, Maki SL, et al. Role of zymogen and activated FX as scaffolds for the inhibition of the blood coagulation FVIIa-tissue factor complex by recombinant nematode anticoagulant protein c2. J Biol Chem 2001; 276: 10063-71.
48. Baugh RJ, Dickinson CD, Ruf W, et al. Exosite interactions determine the affinity of FX for the extrinsic Xase complex. J Biol Chem 2000; 275: 28826-33.
49. Bode W, Huber R. Proteinase-protein inhibitor interaction. Biomed Biochim Acta 1991; 50: 437-46.
50. Huber R, Kukla D, Bode W, et al. Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor. II. Crystallographic refinement at 1.9 A resolution. J Mol Biol 1974; 89: 73-101.
51. Laskowski M Jr, Kato I. Protein inhibitors of proteinases. Annu Rev Biochem 1980; 49: 593-626.
52. Wesselschmidt R, Likert K, Huang Z, et al. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 1993; 4: 661-9.
53. Wesselschmidt R, Likert K, Girard T, et al. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of FXa. Blood 1992; 79: 2004-10.
54. Warshawasky I, Bu G, Mast A, et al. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995; 95: 1173-81.
55. Hembrough TA, Ruiz JF, Papathanassiu AE, et al. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem 2001; 276: 12241-8.
56. Demchenko AP. Recognition between flexible protein molecules: induced and assisted folding. J Mol Recognit 2001; 14: 42-61.
57. Anderson PJ, Nesset A, Dharmawardana KR, et al. Characterization of proexosite I on prothrombin. J Biol Chem 2000; 275: 16428-34.
58. Rezaie AR. Identification of basic residues in the heparin-binding exosite of FXa critical for heparin and factor Va binding. J Biol Chem 2000; 275: 3320-7.
59. Krishnaswamy S, Betz A. Exosites determine macromolecular substrate recognition by prothrombinase. Biochemistry 1997; 36: 12080-6.
60. Kossiakoff AA, Hynes T, de Vos A. Molecular recognition in biological systems: from activation to inhibition. Biochem Soc Trans 1993; 21: 614-8.
61. Roberts BL, Markland W, Ley AC, et al. Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage. Proc Natl Acad Sci USA 1992; 89: 2429-33.
62. Waxman L, Smith DE, Arcuri KE, et al. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-6.
63. Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost 1993; 70: 212-6.
64. van de Locht A, Stubbs MT, Bode W, et al. The ornithodorin-thrombin crystal structure, a key to the TAP enigma? EMBO J 1996; 15:6011-7.
65. Wei A, Alexander RS, Duke J, et al. Unexpected binding mode of tick anticoagulant peptide complexed to bovine factor Xa. J Mol Biol 1998; 283: 147-54.
66. Dunwiddie CT, Waxman L, Vlasuk GP, et al. Purification and characterization of inhibitors of blood coagulation factor Xa from hematophagous organisms. Methods Enzymol 1993; 223: 291-312.
67. Mao SS, Huang J, Welebob C, et al. Identification and characterization of variants of tick anticoagulant peptide with increased inhibitory potency toward human factor Xa. Biochemistry 1995; 34: 5098-103.
68. Aitken A. Analysis of cysteine residues and disulfide bonds. Methods Mol Biol 1994; 32: 351-430.
69. Lindhout T, Fransen J, Willems G. Kinetics of the inhibition of tissue factor-FVIIa by tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 910-5.
70. Esnouf MP, Williams WJ. The isolation and purification of a bovine-plasma protein which is substrate for the coagulation fraction of Russell's viper venom. Biochem J 1962; 84: 62-71.
71. Jackson CM, Hanahan DJ. Studies on bovine factor X. II. Observations on some alterations in zone electrophoresis and chromatographic behavior occurring during purification. Biochemistry 1968; 7: 4506-17.
72. Kirchhofer D, Lipari MT, Moran P, et al. The tissue factor region that interacts with substrates FIX and FX. Biochemistry 2000; 3: 7380-7.
73. Dickinson CD, Kelly CR, Ruf W. Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease FVIIa. Proc Natl Acad Sci USA 1996; 93: 14379-84.
74. Roy S, Paborsky LR, Vehar GA. Self-association of tissue factor as revealed by chemical crosslinking. J Biol Chem 1991; 266: 4665-8.
75. Broze GJ Jr. Binding of human factor VII and VIIa to monocytes. J Clin Invest 1982; 70: 526-35.
76. Le DT, Rapaport SI, Rao LVM. Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces. J Biol Chem 1992; 267: 15447-54.
77. Riewald M, Ruf W. Mechanism coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA 2003; 98: 7742-7.
78. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 2000; 97: 5255-60.
79. Weitz JI, Hirsh J. New anticoagulant drugs. Chest 2001; 119: 95S-107S.